Century Therapeutics, Inc. (IPSC)
Develops off-the-shelf immune cells engineered to treat cancers and autoimmune diseases
$2.05-0.02%Healthcare
StockGlow Score
Leaning Bullish
BearishBullish
1 year ago+285.3%
The outlook
IPSC is trading near the middle of its 52-week range after a flat day. Analyst coverage is sparse, but the average price target sits roughly 132% above the current price, though analyst disagreement is notable. The stock shows a mixed technical picture relative to its moving averages.
What’s behind the score
Price trendMixed vs its moving averages
52-week range62% of the way from its 52-week low to high
Price targetAvg target +132% vs current price
Analyst price target
~12-month · 4 analysts$4.75average target+131.7% vs now
Now $2.05
Low $2.00High $8.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$369.7M
52-wk high
$3.04
52-wk low
$0.44
50-day avg
$2.26
200-day avg
$1.73
Trailing P/E
—